Numerous targeted therapies, including those against VEGF, Kras, EGFR, ALK and immunotherapies such as PD1 and CTLA-4, have already gained approval for treating NSCLC (as reviewed in [32,33,34]). Here, EGFR is linked to non-small cell lung carcinoma.